Mumbai, May 22 -- Biocon Biologics (BBL) announced that the Government of Malaysia has agreed to extend the current contract period of 36 months under the existing insulin supply agreement with its subsidiary in Malaysia, Biocon Sdn. Bhd., and Duopharma Marketing Sdn. Bhd. (DMktg), for an additional six (6) months effective from 29 April 2025 until 28 October2025.
Published by HT Digital Content Services with permission from Capital Market....